Tag Archives: Aduhelm

‘I don’t like it:’ Biogen’s latest Alzheimer’s ad rouses fresh Aduhelm concerns—and some defense

Maybe you occasionally forget appointments or social events, or lose your train of thought in a conversation. Maybe you’re feeling depressed or overwhelmed when making a decision.  According to a online symptoms quiz from Biogen and Japanese partner Eisai, those are just a handful of signs of mild cognitive impairment (MCI), an early indication of… Read More »

How Aduhelm, an Unproven Alzheimer’s Drug, Got Approved

Advertisement Continue reading the main story Supported by Continue reading the main story How an Unproven Alzheimer’s Drug Got Approved Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab. The F.D.A. conducted an internal inquiry this year after allegations were… Read More »

High-profile Biogen ads hype early Alzheimer’s detection as hospitals reject Aduhelm prescriptions

How do you sell an Alzheimer’s treatment mired in controversy over its disputed benefits? Biogen is turning to “Jim and Jane” for help.  That’s the couple grappling with the memory-robbing disease that Biogen and Japanese partner Eisai have placed at the center of their new marketing campaign, “It’s Time We Know.” The campaign is designed… Read More »